.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Queensland Health
Argus Health
UBS
Julphar
Citi
Colorcon
Boehringer Ingelheim
Baxter
QuintilesIMS

Generated: September 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019938

« Back to Dashboard
NDA 019938 describes NOVOLIN R, which is a drug marketed by Novo Nordisk Inc and is included in two NDAs. It is available from two suppliers. Additional details are available on the NOVOLIN R profile page.

The generic ingredient in NOVOLIN R is insulin recombinant purified human. There are thirty-eight drug master file entries for this compound. Additional details are available on the insulin recombinant purified human profile page.

Summary for NDA: 019938

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 019938

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NOVOLIN R
insulin recombinant human
INJECTABLE;INJECTION 019938 NDA Novo Nordisk 0169-1833 0169-1833-02 1 VIAL in 1 CARTON (0169-1833-02) > 10 mL in 1 VIAL
NOVOLIN R
insulin recombinant human
INJECTABLE;INJECTION 019938 NDA Novo Nordisk 0169-1833 0169-1833-11 1 VIAL in 1 CARTON (0169-1833-11) > 10 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:OTCDosage:INJECTABLE;INJECTIONStrength100 UNITS/ML
Approval Date:Jun 25, 1991TE:RLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Farmers Insurance
Covington
Cerilliant
Boehringer Ingelheim
Johnson and Johnson
Novartis
Argus Health
Citi
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot